Friday, 25 September 2026European Markets

BELYSSE GROUP Stock Impressive Jump Before The Weekend, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with BELYSSE GROUP (BELYS.BR) jumping 11.54% to €0.87 on Friday, following the last session's downward trend. BEL 20 jumped 0.09% to €4,112.91, after two successive sessions in a row of gains, on what was a somewhat up trend trading session today.

About BELYSSE GROUP

Belysse Group NV engages in the production and sale of textile floor coverings for commercial and residential applications in Europe, North America, and internationally. The company designs, manufactures, and distributes broadloom carpets and modular carpet tiles for offices and public projects. It commercializes its products under the Bentley, modulyss, arc edition, and ITC brands. The company was formerly known as Balta Group NV and changed its name to Belysse Group NV in October 2022. Belysse Group NV was founded in 1964 and is headquartered in Waregem, Belgium. Belysse Group NV is a subsidiary of LSF9 Belysse Holdco S.à r.l.

Earnings Per Share

As for profitability, BELYSSE GROUP has a trailing twelve months EPS of €-0.31.

More news about BELYSSE GROUP (BELYS.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com